Kodu・Aktsiate loetelu・TransMedics Group Inc

TransMedics Group Inc

Suletud

SektorTervishoid

83.46 4.08

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

81.2

Max

83.88

Põhinäitajad
By Trading Economics
Sissetulek	-98M 7.3M
Müük	13M 174M
P/E Sektori keskmine	18.661 68.51
Aktsiakasum	0.3
Kasumimarginaal	4.206
Töötajad	898
EBITDA	-4.9M 28M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+12.31% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	28. okt 2026

Turustatistika
By TradingEconomics
Turukapital	-535M 2.8B
Eelmine avamishind	79.38
Eelmine sulgemishind	83.46

Uudiste sentiment

By Acuity

58%

42%

259 / 340 Pingereas Healthcare

TransMedics Group Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 19:22 UTC

News

TransMedics shares are higher as Piper Sandler and Needham adjust price targets, reflecting positive sentiment from multiple analysts during Friday's trading session.

6. aug 2026, 20:03 UTC

Social Media

News

Transmedics Group Inc shares are higher, supported by positive Q2 results and mentions in a fund manager's portfolio, despite potential short-term volatility concerns.

5. aug 2026, 20:03 UTC

Social Media

News

TransMedics Group Inc. shares are lower following mixed quarterly results and an earnings miss, prompting price target cuts from Piper Sandler and UBS.

4. aug 2026, 23:02 UTC

News

Social Media

Transmedics Group shares are lower in after-market hours following Q2 results, where adjusted EPS of $0.44 missed expectations despite revenue surpassing estimates.

3. aug 2026, 19:51 UTC

Social Media

News

TransMedics Group Inc. shares are rising, despite an analyst downgrade to a $106 price target from $142, amid positive social media discussions.

30. juuli 2026, 19:03 UTC

Transmedics Group Inc shares are lower during Thursday's session, with no specific news identified. Broader market uncertainty may be influencing the decline.

29. juuli 2026, 23:36 UTC

Transmedics Group Inc. shares are lower in after-market trading, reflecting broader market volatility amid rising interest rates and geopolitical tensions.

28. juuli 2026, 19:46 UTC

Transmedics Group Inc shares are higher today, advancing since Monday. The stock peaked earlier but pulled back from a session high.

27. juuli 2026, 15:16 UTC

Social Media

News

Transmedics Group Inc is higher today amid social media discussions on its undervaluation and expectations for significant profit by 2028.

24. juuli 2026, 20:02 UTC

Social Media

Transmedics Group Inc gains amid positive feedback from Jefferies on its technology and growth prospects, aligning with strength in the Health Care Equipment sector.

22. juuli 2026, 19:46 UTC

Transmedics Group Inc shares are lower today, reflecting ongoing declines. The stock's volatility coincides with rising crude oil prices amid geopolitical tensions.

21. juuli 2026, 14:36 UTC

Social Media

Transmedics Group's shares are higher today following the first lung transplant using its OCS warm-perfusion device, enhancing organ preservation and clinical outcomes.

20. juuli 2026, 12:26 UTC

Social Media

TransMedics Group Inc shares are higher in pre-market trading amid strong operational growth, with flights exceeding 36 per day and projected revenue of $3 billion by 2032.

Võrdlus sarnastega

Hinnamuutus

TransMedics Group Inc Prognoos

Hinnasiht

By TipRanks

12.31% tõus

12 kuu keskmine prognoos

Keskmine 94.22 USD 12.31%

Kõrge 122 USD

Madal 65 USD

Põhineb 10 Wall Streeti analüütiku instrumendi TransMedics Group Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi TransMedics Group Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

259 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.